In September 2016 Tonix reported the failure of its Phase III trial of TNX - 102 for fibromyalgia .
In September 2016 Tonix said it was abandoning that line of development .
In September 2016 Tonix reported the failure of its Phase III trial of TNX - 102 for fibromyalgia and said it was abandoning that line of development .